Journal article
Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor
Neuroreport, Vol.12(10), pp.2131-2136
07/20/2001
DOI: 10.1097/00001756-200107200-00018
PMID: 11447321
Abstract
Anandamide (ANA) alters sleep by increasing the amount of time spent in slow wave sleep 2 (SWS2) and rapid eye movement sleep (REMS) at the expense of wakefulness (W) in rats. In this report, we describe a similar effect of ANA when injected itracerebroventricularly (i.c.v.) or into the peduriculopontine tegmental nucleus (PPTg) and the lack of an effect when ANA is administered into the medial preoptic area (MPOA). Furthermore, the i.c.v. or PPTg administration of SR141716A, a CB1 antagonist, or U73122, a PLC inhibitor, 15 min prior to ANA, readily prevents the ANA induced changes in sleep. The present results suggest that a cannabinoid system in the PPTg may be involved in sleep regulation and that the cannabinoid effect is mediated by the CB1 receptor coupled to a PLC second messenger system.
Details
- Title: Subtitle
- Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor
- Creators
- Eric Murillo-RodríguezRafael CabezaMónica Méndez-DíazLuz NavarroOscar Prospéro-García
- Resource Type
- Journal article
- Publication Details
- Neuroreport, Vol.12(10), pp.2131-2136
- Publisher
- Lippincott Williams & Wilkins, Inc
- DOI
- 10.1097/00001756-200107200-00018
- PMID
- 11447321
- ISSN
- 0959-4965
- eISSN
- 1473-558X
- Language
- English
- Date published
- 07/20/2001
- Academic Unit
- Molecular Physiology and Biophysics
- Record Identifier
- 9984695830502771
Metrics
10 Record Views